-
Mashup Score: 4Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS) - 6 month(s) ago
Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical performance standards, merits, and limitations of currently available imaging methods. Following guidance from the International Myeloma Working Group and the National Institute for Clinical Excellence in the United Kingdom, the Myeloma Response Assessment and Diagnosis System (or MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment. This consensus proposes a core clinical protocol for whole-body MRI and an extended protocol for advanced assessments. Published under a CC BY 4.0 license. Online supplemental material is available for this articl
Source: pubs.rsna.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 13Weight-Loss Drugs Estimated to Save Airlines Millions - 8 month(s) ago
Airlines and planemakers obsess about reducing jet-fuel consumption by constantly finding new ways to reduce aircraft weight. They may have new allies in Ozempic and other similar slimming medications.
Source: www.bloomberg.comCategories: Latest Headlines, Oncologists2Tweet-
RT @BallouxFrancois: Well, that's an angle to the discussion on weight-loss drugs I hadn't considered ... 😐 https://t.co/sAjVueIDKo
-
-
Mashup Score: 19
Perspective from The New England Journal of Medicine — The New USPSTF Mammography Recommendations — A Dissenting View
Source: www.nejm.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @EricTopol: New @NEJM Mass screening for breast cancer for women in their 40s makes no sense https://t.co/5zxR5R8G0W @StevenWoloshin and…
-
-
Mashup Score: 1ESH - European School of Haematology - 12 month(s) ago
7th Translational Research Conference: Multiple Myeloma October 04 – October 06, 2024 – Mandelieu-La Napoule, France – #ESHMM2024 Chairs : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch Information 7th Translational Research…
Categories: Latest Headlines, Oncologists2Tweet-
RT @ESHaematology: 📣 #ESHMM2024 SAVE THE DATE: October 4-6, 2024 REGISTRATION IS OPEN, proceed here ➡ https://t.co/o6pN7YBzXv 📍 Join us in…
-
-
Mashup Score: 17Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
RT @mvmateos: AddThis | Home https://t.co/BbXa8TmS8G
-
-
Mashup Score: 7Volume 141 Issue 14 | Blood | American Society of Hematology - 1 year(s) ago
Read Volume 141 Issue 14 of Blood.
Source: ashpublications.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @BloodJournal: The newest issue of Blood is now available. https://t.co/mvVUTUQjyX #hematology https://t.co/2kJNnPmS4g
-
-
Mashup Score: 13
Blood Podcast – Season 5, Episode 14 | Blood | American Society of Hematology Lenalidomide and genetic profiling in myeloma, T-cell immunotherapy upregulates AML cell MHC-class II, and young fecal microbiota rejuvenate HSCs In this week’s episode we will review optimizing the value of post-transplant lenalidomide maintenance in multiple myeloma. Next, T-cell immunotherapies…
Source: ashpublications.orgCategories: Latest Headlines, Oncologists2Tweet-
Great to see the results of our collaborative #UKMRA study on extended genetic profiling for len maintenance in patients with #myeloma. Many thanks to @BloodJournal editors, reviewers and @mvmateos for a fantastic comment - and the podcast for tl;dr! https://t.co/uiGBhO2V0p https://t.co/MZPHOynmYu
-
-
Mashup Score: 4Seminar by Sir Rory Collins, FRS, FMedSci | Evolve or die: the urgent need to streamline RCTs - 1 year(s) ago
Evolve or die: the urgent need to streamline RCTs About the Event: There is an urgent need to develop comprehensive guidelines based on the scientific principles underlying randomized, controlled trials that focus on those aspects that really matter for both generating reliable findings and ensuring patient…
Source: mailchi.mpCategories: Latest Headlines, Oncologists2Tweet-
RT @consiliumsci: Join Consilium next week to meet Sir Rory Collins and discuss RCTs. Sign up https://t.co/SCs8RJAy15 @Oxford_NDPH @UKRIO @…
-
-
Mashup Score: 1
Britain faces a severe shortage of doctors who work both in the NHS and at universities, which threatens medical research and teaching, the Lords science and technology committee has warned the government. The peers sent the findings of their inquiry into academic medicine to Steve Barclay, the health secretary, on Thursday, warning that “the clinical research environment in the NHS is on a dangerous precipice”.
Source: Financial TimesCategories: Latest Headlines, Oncologists2Tweet-
RT @jansen_marnix: https://t.co/u1pcDdGkSU
-
-
Mashup Score: 1UK signs deal with BioNTech for cutting-edge cancer trials - 1 year(s) ago
The UK government is partnering with German Covid-19 vaccine maker BioNTech to enrol up to 10,000 patients in clinical trials for cutting-edge cancer treatments. BioNTech, which partnered with US pharmaceutical group Pfizer to develop a Covid jab that was the world’s bestselling by revenue, said on Friday that it would open a research and development centre with 75 staff in Cambridge.
Source: Financial TimesCategories: Latest Headlines, Oncologists2Tweet-
Will be very interesting to see how this will work in practice - a fantastic, extremely scalable technology. And of course hoping #myeloma patients may be included as well! @BioNTech_Group @NCRI_partners #MMsm https://t.co/7MSAAqCCHX
-
Comment to Q1: No contrast needed for myeloma WB-MRI with diffusion weighting (MY-RADS, below). Also, no ionising radiation–important for renally impaired and patients who will have many scans in their life: SMM, EMD, oligo-/asecretory MM. https://t.co/hjEKzZ2vdr https://t.co/RCSLr6ocl0